Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Povidone-Iodine for COVID-19: real-time meta analysis of 12 studies
Covid Analysis, January 18, 2022, DRAFT
https://c19pvpi.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mohamed (RCT) 86% 0.14 [0.01-2.21] viral+ 0/5 3/5 Improvement, RR [CI] Treatment Control Choudhury (RCT) 88% 0.12 [0.03-0.50] death 2/303 17/303 Choudhury (RCT) 84% 0.16 [0.09-0.28] hosp. 12/303 77/303 Choudhury (RCT) 96% 0.04 [0.02-0.07] viral+ 8/303 213/303 Guenezan (RCT) 63% 0.37 [0.06-1.63] viral load 12 (n) 12 (n) Elzein (DB RCT) 89% 0.11 [0.01-1.00] viral load 25 (n) 9 (n) Arefin (RCT) 79% 0.21 [0.08-0.54] viral+ 4/27 19/27 Arefin (RCT) 89% 0.11 [0.03-0.41] viral+ 2/27 19/27 Arefin (RCT) 53% 0.47 [0.26-0.85] viral+ 9/27 19/27 Arefin (RCT) 80% 0.20 [0.09-0.44] viral+ 5/27 25/27 Arefin (RCT) 64% 0.36 [0.21-0.62] viral+ 9/27 25/27 Arefin (RCT) 74% 0.26 [0.19-0.37] viral+ 29/135 44/54 Baxter (RCT) 65% 0.35 [0.01-8.27] hosp. 0/37 1/42 OT​1 Baxter (RCT) 79% 0.21 [0.01-4.24] hosp./ER 0/37 2/42 OT​1 Baxter (RCT) 57% 0.43 [0.20-0.94] no recov. 6/27 18/35 OT​1 Baxter (RCT) 37% 0.63 [0.19-2.05] transmission 4/37 6/35 OT​1 Pablo-Marcos 29% 0.71 [0.32-1.56] viral load 31 (n) 40 (n) Pablo-Marcos 9% 0.91 [0.20-4.16] viral load 31 (n) 40 (n) Seneviratne (RCT) 33% 0.67 [0.50-0.91] viral load 4 (n) 2 (n) Zarabanda (RCT) -27% 1.27 [0.26-6.28] no recov. 3/13 2/11 OT​1 Zarabanda (RCT) -50% 1.50 [0.31-7.30] no recov. 3/11 2/11 OT​1 Zarabanda (RCT) 0% 1.00 [0.19-5.24] viral+ 2/7 2/7 OT​1 Jamir 57% 0.43 [0.27-0.69] death 39/163 62/103 Ferrer (RCT) 34% 0.66 [0.02-19.0] viral load 9 (n) 12 (n) Seet (CLUS. RCT) 45% 0.55 [0.38-0.80] symp. case 42/735 64/619 OT​1 Seet (CLUS. RCT) 31% 0.69 [0.37-1.01] cases 338/735 433/619 OT​1 povidone-iodine COVID-19 outcomes c19pvpi.com Jan 18, 2022 1 OT: comparison with other treatment Favors povidone-iodine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit